Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.98
+0.13004.56%
Post-market: 2.980.00000.00%16:57 EDT
Volume:128.51K
Turnover:380.31K
Market Cap:99.46M
PE:-8.85
High:3.05
Open:2.88
Low:2.83
Close:2.85
52wk High:5.46
52wk Low:2.33
Shares:33.38M
Float Shares:30.46M
Volume Ratio:1.04
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3367
EPS(LYR):-0.3367
ROE:-67.17%
ROA:-38.83%
PB:6.56
PE(LYR):-8.85

Loading ...

Anixa Biosciences Announces Transfer of Ind for Breast Cancer Vaccine From Cleveland Clinic

THOMSON REUTERS
·
Dec 15, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM

Reuters
·
Dec 12, 2025

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 12, 2025

Anixa Biosciences Reports Positive Phase 1 Results for Investigational Breast Cancer Vaccine

Reuters
·
Dec 12, 2025

Anixa Biosciences Inc - Vaccine Safe and Well Tolerated at Maximum Dose

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

THOMSON REUTERS
·
Dec 12, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Dec 10, 2025

Anixa Biosciences Secures WHO Approval for CAR-T Therapy Name

Reuters
·
Nov 17, 2025

Anixa Biosciences Announces World Health Organization (Who) Approval of International Non-Proprietary Name for Its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

THOMSON REUTERS
·
Nov 17, 2025

Anixa Biosciences CEO to Join Water Tower Research Fireside Chat

Reuters
·
Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Cartesian Therapeutics (RNAC) and Anixa Biosciences (ANIX)

TIPRANKS
·
Nov 07, 2025

BRIEF-Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Reuters
·
Nov 05, 2025

Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters
·
Nov 05, 2025

Anixa Biosciences to Present at Spartan Capital Securities Second Annual Investor Conference

Reuters
·
Oct 23, 2025

Anixa Biosciences Secures Chinese Patent for Breast Cancer Vaccine Technology

Reuters
·
Oct 20, 2025

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Oct 20, 2025

Anixa Biosciences Completes Phase 1 Breast Cancer Vaccine Trial and Plans Results Presentation in 2025

Reuters
·
Oct 08, 2025

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 07, 2025

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

THOMSON REUTERS
·
Oct 07, 2025

Anixa Biosciences Completes Final Patient Visits in Breast Cancer Vaccine Trial; Full Results to Be Presented at December Symposium

Reuters
·
Oct 07, 2025